Application of membrane protein CD81 in early forecasting, parting, diagnosis and treatment of eclampsia

A pre-eclampsia and membrane protein technology, applied in medical preparations containing active ingredients, disease diagnosis, gene therapy, etc., can solve problems such as CD81 that has not yet been seen

Active Publication Date: 2015-06-10
NANJING DRUM TOWER HOSPITAL
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But there is no related

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of membrane protein CD81 in early forecasting, parting, diagnosis and treatment of eclampsia
  • Application of membrane protein CD81 in early forecasting, parting, diagnosis and treatment of eclampsia
  • Application of membrane protein CD81 in early forecasting, parting, diagnosis and treatment of eclampsia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Example 1: CD81 is expressed in the placenta and serum of patients with early-onset severe PE

[0037] 1. Materials, reagents, equipment

[0038] 1.1 Human placenta tissue and serum source

[0039] Singleton primiparas who had elective cesarean section delivery in the Drum Tower Hospital Affiliated to Nanjing University School of Medicine between October 2011 and October 2014 were selected and signed informed consent. Chronic hypertension, pre-pregnancy diabetes, kidney disease, premature rupture of membranes, Infectious diseases and other pregnancy complications and complications. The diagnostic criteria for severe PE were according to the 23rd edition of Williams Obstetrics. Venous blood was drawn immediately after the pregnant woman was admitted to the hospital, and the serum was kept in a -80°C refrigerator after centrifugation. Within 10 minutes after the delivery of the placenta, several pieces of tissue with a size of about 1.0cm×1.0cm×1.0cm in the middle of t...

Embodiment 2

[0057] Example 2: The effect of CD81 on the invasion function of placental primary cytotrophoblasts (CTBs)

[0058] 1. Materials, reagents, equipment

[0059] 1.1 Collection of human villi in the first trimester

[0060] The fresh villi of pregnant women who requested artificial abortion due to early pregnancy and underwent abortion in the Family Planning Department of Nanjing Drum Tower Hospital were collected. Pregnant women without any disease, gestational weeks in 6-8w.

[0061] 1.2 Main reagents and equipment

[0062] Collagenase, hyaluronidase, DNA inhibitory enzyme, sodium pyruvate, glutamine, Hepes balance solution, BSA (Sigma); Nutridoma-SP (Roche); Percoll (GE Healthcare); Matrigel (BD); DME H medium, 0.05% trypsin, fetal bovine serum (FBS), penicillin and streptomycin, gentamicin (Invitrogen); Ad-CTL adenovirus and Ad-Flag-CD81 adenovirus (GENECHEM, Shanghai).

[0063] Ultra-clean table (Sujing Group Antai Company), high-speed centrifuge (Germany Heraeus Company...

Embodiment 3

[0074] Example 3: CD81 adenovirus-induced PE model in rats

[0075] 1.1 Materials and grouping

[0076] SPF grade SD rats were randomly divided into two groups: control group (Ad-CTL group) and Ad-Flag-CD81 group (n=8). According to 1:1 female and male cages, observe the vaginal plug, see the vaginal plug and record it as the 0th day of pregnancy. The amount of virus injected into each mouse was 3×10 9 PFU. The administration method is tail vein injection, and the injection speed is controlled by an intravenous injection pump. The administration time was the 5th day of pregnancy, and the mice were killed on the 15th day of pregnancy. At the same time, non-pregnant rats were randomly divided into two groups: control group (Ad-CTL group) and Ad-Flag-CD81 group (n=5), and were sacrificed on the 10th day after injection.

[0077] 1.2 Blood pressure monitoring

[0078] The systolic blood pressure of the tail artery was measured every day from one week before the experiment to t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of a membrane protein CD81 in early forecasting, parting, diagnosis and treatment of eclampsia. Clinical investigation, an in-vitro molecular experiment and an animal experiment show that through suppression of the invasion ability of nurse cells, CD81 is capable of leading the remodeling obstacle of the uterine spiral artery, so that PE illness is caused. Therefore, the CD81 can be used as a marking molecule for forecasting PE and is possibly used as a marking molecule for PE parting or a target for preventing and treating PE.

Description

technical field [0001] The invention belongs to the field of high-risk pregnancy in obstetrics and gynecology, and relates to the application of membrane protein CD81 in the prediction, typing, diagnosis and treatment of preeclampsia. Background technique [0002] Preeclampsia (PE) is a unique complication of pregnancy, with hypertension and proteinuria as the main clinical features after 20 weeks of gestation. It can cause multiple organ dysfunction in pregnant women, intrauterine hypoxia, fetal growth restriction, iatrogenic premature birth, etc., and is an important reason for the increase in maternal and perinatal mortality. The etiology of PE is unknown. Judging from the relationship between onset time and gestational age, it is currently divided into early onset and late onset, indicating that the etiology is heterogeneous. However, there is no more accurate classification method, which seriously affects the prediction of PE. Establishment of preventive and targeted t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N33/68G01N33/577A61K39/39A61K48/00A61P15/00
CPCA61K45/00G01N33/689G01N2800/368G01N2800/50
Inventor 胡娅莉周艳刁振宇沈莉颜桂军赵光峰
Owner NANJING DRUM TOWER HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap